ライフサイエンスコーパス: deoxy-ATP

1 o thin filament activation by substituting 2 deoxy-ATP (dATP; a strong cross-bridge augmenter) for AT

2 Replacing ATP with 2 deoxy-ATP (dATP) increased F-actin speed for both groups

3 utanedione monoxime) or augmentation (with 2 deoxy-ATP) had no greater effect in cardiac muscle with

4 ucture of hOAS1 in complex with dsRNA and 2'-deoxy ATP at 2.7 A resolution, which reveals the mechani

5 The time-course of VCF responses to ATP, 2'-deoxy ATP, 3'-deoxy ATP, Ap5A and alphabetameATP were ag

6 Substitution of 2'-deoxy ATP (dATP) for ATP as substrate for actomyosin res

7 2'-deoxy-ATP (dATP) improves cardiac function by increasing

8 Here we examined the effect of 2'-deoxy-ATP (dATP), a naturally occurring energy substrate

9 ion (NO3 (-) ) and N(6) -(2-phenylethyl)-2'-deoxy-ATP (d-PATP), which almost completely rectifies th

10 e custom synthesized N(6)-(2-phenylethyl)-2'-deoxy-ATP (P-dATP), an analog combining the chemical mod

11 ngly, an ATP analogue, N6-(2-phenylethyl)-2'-deoxy-ATP (P-dATP), can increase the open probability (P

12 Here we show that 2'-deoxy-ATP (dATP), but not 3'-deoxy-ATP, increases the ac

13 ATP, 2-deoxy ATP (dATP), CTP, and UTP support isometric force a

14 mouse model with elevated skeletal muscle 2-deoxy-ATP (dATP) was used to study how myosin activators

15 The naturally occurring nucleotide 2-deoxy-ATP (dATP) is a myosin activator that enhances cro

16 s of cardiac trabeculae with either ATP or 2-deoxy-ATP (dATP) as the substrate for contraction.

17 y demonstrated that cardiac myosin can use 2-deoxy-ATP (dATP) as an energy substrate, that it enhance

18 ntrol by substitution of ATP (5.0 mM) with 2-deoxy-ATP (dATP) (5.0 mM) or by lowering [ATP] to 0.5 mM

19 were altered by either replacing ATP with 2-deoxy-ATP (dATP) or by reducing [ATP].

20 oss-bridge cycling rate was increased with 2-deoxy-ATP.

21 se of VCF responses to ATP, 2'-deoxy ATP, 3'-deoxy ATP, Ap5A and alphabetameATP were agonist dependen

22 differences with respect to inhibition by 3'-deoxy-ATP.

23 -(7-diethylaminocoumarin-3-carbonylamino)-3'-deoxy-ATP (deac-aminoATP), which undergoes a 20-fold inc

24 luenza RNA polymerase, the K(i) value for 3'-deoxy-ATP (0.4-0.6 microM) is approximately 100-fold low

25 Whereas the K(i) value for 3'-deoxy-ATP (105-117 microM) is similar to the K(m) value

26 MANT-3'-dATP [2'-O-(N-methylanthraniloyl)-3'-deoxy-ATP] (Ki, 16.7 nM).

27 we show that 2'-deoxy-ATP (dATP), but not 3'-deoxy-ATP, increases the activity of G551D-CFTR by appro

28 In the active site, 3'-deoxy-ATP and a single metal ion are well positioned for

29 g protein B (HalB) is an NTase that converts deoxy-ATP into single-stranded DNA oligomers.

30 of the 2'-deoxyribose leads to ligands (mant-deoxy-ATP [dATP], mant-deoxy-ADP) with inverse agonist a

31 of mavacamten and reduced in the presence of deoxy-ATP.

32 as active with ATP and partially active with deoxy-ATP, but lacked measurable activity with other nuc